M. Zuehlsdorf

发表

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor

G. Wensing, D. Kubitza, M. Becka, 2005, Clinical pharmacology and therapeutics.

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects

W. Mueck, D. Kubitza, M. Becka, 2007, Journal of clinical pharmacology.

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin

W. Mueck, D. Kubitza, M. Becka, 2006, Journal of clinical pharmacology.

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

W. Mueck, D. Kubitza, M. Becka, 2006, Journal of clinical pharmacology.

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.

W. Mueck, D. Kubitza, M. Becka, 2007, British journal of clinical pharmacology.

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.

W. Mueck, D. Kubitza, M. Becka, 2007, International journal of clinical pharmacology and therapeutics.

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

W. Mueck, D. Kubitza, M. Becka, 2006 .

Interleukin 10 inhibits cytokine production of human AML cells.

V. Diehl, F. Westermann, H. Tesch, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects

G. Wensing, D. Kubitza, M. Becka, 2003 .

CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4- hydroperoxycyclophosphamide-purged bone marrow

Richard J. Jones, O. Colvin, H. Braine, 1987 .

Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation.

O. Colvin, J. Hilton, M. Zuehlsdorf, 1987, Blood.

Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation.

O. Colvin, J. Hilton, M. Zuehlsdorf, 1987, Blood.

Final analysis: A multicenter phase I study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer with bone metastases after chemotherapy.

M. Wirth, H. Lannert, S. Zastrow, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis

J. Tchinda, J. Kienast, M. Zuehlsdorf, 2004, Leukemia.

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Michael Becka, G. Wensing, D. Kubitza, 2005, European Journal of Clinical Pharmacology.

CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow.

Janice, Michael, Scott, 1987, Blood.

Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapse.

W. Hiddemann, W. Ludwig, T. Büchner, 1990, Haematology and blood transfusion.

Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC)

J. Kienast, W. Sibrowski, M. Zuehlsdorf, 2001, Bone Marrow Transplantation.

Recombinant human GM-CSF following chemotherapy in high-risk AML.

W. Hiddemann, W. Ludwig, G. Innig, 1990, Bone marrow transplantation.

Final analysis: A multicenter phase I study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer with bone metastases after chemotherapy.

M. Wirth, H. Lannert, S. Zastrow, 2012, Journal of Clinical Oncology.

Solitary plasmacytoma of the lung with coexisting sarcoid-like lesions

K. Juergens, M. Semik, W. Berdel, 2008, Annals of Hematology.

72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors

J. Verweij, H. Gelderblom, P. Rajagopalan, 2006 .

Impact of pharmacogenetics on health care and health economics

P. Sagnier, T. Weihrauch, G. Glaeske, 2001, International Journal of Pharmaceutical Medicine.